Improved overall survival for Stage III NSCLC patients treated with curative-intended therapy from 2010 to 2018–a cohort study in Denmark

References

• Globocan [Internet]. GLOBOCAN 2020 updated 2021, March; [cited 2023 April 3]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/208-denmark-fact-sheets.pdf.
   Google Scholar
• NORDCAN AotNCR [Internet]. NORDCAN, Association of the Nordic Cancer Registries; 2022. IARC 1965–2023. [Cited 2023 April 3] Available from: https://nordcan.iarc.fr/en.
   Google Scholar
• Jakobsen E, Rasmussen TR, Green A. Mortality and survival of lung cancer in Denmark: results from the Danish lung cancer group 2000–2012. Acta Oncol. 2016;55 Suppl 2(sup2):2–9. doi: 10.3109/0284186X.2016.1150608.
   PubMedGoogle Scholar
• Engholm G, Ferlay J, Christensen N, et al. NORDCAN–a nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725–736. doi: 10.3109/02841861003782017.
   PubMed Web of Science ®Google Scholar
• Howlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640–649. doi: 10.1056/NEJMoa1916623.
   PubMed Web of Science ®Google Scholar
• Mouritzen MT, Carus A, Ladekarl M, et al. Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced NSCLC-real world efficacy. Cancers. 2021;13(19):4846. doi: 10.3390/cancers13194846.
   PubMed Web of Science ®Google Scholar
• Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111(6):1710–1717. doi: 10.1378/chest.111.6.1710.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, De Ruysscher D, Eberhardt WE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi89–98. doi: 10.1093/annonc/mdt241.
   PubMedGoogle Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193–203. doi: 10.1016/j.chest.2016.10.010.
   PubMed Web of Science ®Google Scholar
• Mirsadraee S, Oswal D, Alizadeh Y, et al. The 7th lung cancer TNM classification and staging system: review of the changes and implications. World J Radiol. 2012;4(4):128–134. doi: 10.4329/wjr.v4.i4.128.
   PubMedGoogle Scholar
• Dansk Lunge Cancer Gruppe. [Danish Lung Cancer Group], DLCG, www.lungecancer.dk. [Internet]. Danish. [Cited 2023 April 3] Available from: https://www.lungecancer.dk/referenceprogram/.
   Google Scholar
• Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1–iv21. doi: 10.1093/annonc/mdx222.
   PubMed Web of Science ®Google Scholar
• Jain NA, Otterson GA. Immunotherapy in inoperable stage III non-small cell lung cancer: a review. Drugs Context. 2019;8:212578–212576. doi: 10.7573/dic.212578.
   PubMedGoogle Scholar
• Patel SA, Weiss J. Advances in the treatment of non-small cell lung cancer: immunotherapy. Clin Chest Med. 2020;41(2):237–247. doi: 10.1016/j.ccm.2020.02.010.
   PubMed Web of Science ®Google Scholar
• Remon J, Levy A, Singh P, et al. Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial? Ther Adv Med Oncol. 2022;14:17588359221113268. doi: 10.1177/17588359221113268.
   Web of Science ®Google Scholar
• Ferro A, Sepulcri M, Schiavon M, et al. The multidisciplinary approach in stage III non-small cell lung cancer over ten years: from radiation therapy optimisation to innovative systemic treatments. Cancers (Basel). 2022;14(22):5700. doi: 10.3390/cancers14225700.
   PubMed Web of Science ®Google Scholar
• Danmarks Statistik [Denmark’s Statistics] [Internet]. HFAUDD Danish[ cited 2023 April 3] Available from: https://www.dst.dk/da/Statistik/dokumentation/Times/moduldata-for-uddannelse-og-kultur/hfaudd.
   Google Scholar
• Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474. doi: 10.1245/s10434-010-0985-4.
   PubMed Web of Science ®Google Scholar
• R Core Team. 2020. R: a language and environment for statistical computing. [Internet]. R Foundation for Statistical Computing, Austria, Vienna. [Cited 2023 April 3] Available from: https://www.R-project.org/.
   Google Scholar
• Łazar-Poniatowska M, Bandura A, Dziadziuszko R, et al. Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review). Transl Lung Cancer Res. 2021;10(4):2018–2031. doi: 10.21037/tlcr-20-704.
   PubMed Web of Science ®Google Scholar
• Casal-Mouriño A, Ruano-Ravina A, Lorenzo-González M, et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10(1):506–518. doi: 10.21037/tlcr.2020.03.40.
   PubMed Web of Science ®Google Scholar
• Muchnik E, Loh KP, Strawderman M, et al. Immune checkpoint inhibitors in real-world treatment of older adults with non-small cell lung cancer. J Am Geriatr Soc. 2019;67(5):905–912. doi: 10.1111/jgs.15750.
   PubMed Web of Science ®Google Scholar
• Ryan KJ, Skinner KE, Fernandes AW, et al. Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer. Future Oncol. 2019;15(25):2943–2953. doi: 10.2217/fon-2018-0939.
   PubMed Web of Science ®Google Scholar
• Daly ME, Singh N, Ismaila N, et al. Management of stage III non-small-cell lung cancer: ASCO guideline. J Clin Oncol. 2022;40(12):1356–1384. doi: 10.1200/JCO.21.02528.
   PubMed Web of Science ®Google Scholar
• Käsmann L, Taugner J, Eze C, et al. Performance status and its changes predict outcome for patients with inoperable stage III NSCLC undergoing multimodal treatment. Anticancer Res. 2019;39(9):5077–5081. doi: 10.21873/anticanres.13701.
   PubMed Web of Science ®Google Scholar
• Lilenbaum RC, Cashy J, Hensing TA, et al. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol. 2008;3(2):125–129. doi: 10.1097/JTO.0b013e3181622c17.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350. doi: 10.1056/NEJMoa1809697.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40(12):1301–1311. doi: 10.1200/JCO.21.01308.
   PubMed Web of Science ®Google Scholar
• Neumann M, Murphy N, Seetharamu N. The evolving role of PD-L1 inhibition in non-small cell lung cancer: a review of durvalumab and avelumab. Cancer Med J. 2022;5(1):31–45.
   PubMedGoogle Scholar
• Lundberg FE, Andersson TM, Lambe M, et al. Trends in cancer survival in the nordic countries 1990-2016: the NORDCAN survival studies. Acta Oncol. 2020;59(11):1266–1274. doi: 10.1080/0284186X.2020.1822544.
   PubMed Web of Science ®Google Scholar